Han Lee, Ph.D.

Han Lee

Han Lee, Ph.D., MBA, is the Chief Financial Officer at Neogene Therapeutics. Before joining Neogene, Dr. Lee served as Chief Financial Officer of Arcellx where he oversaw the company’s financial operations, corporate financings, and was instrumental in its growth from pre-clinical to clinical. Previously, Dr. Lee worked in the Corporate Development and Ventures group at […]

David Lund, Ph.D.

David Lund

David Lund, Ph.D., is the Vice President, Intellectual Property at Neogene Therapeutics. Before coming to Neogene, Dr. Lund served most recently as Senior IP Counsel at Agenus, where his responsibilities included managing IP issues for Agenus’ affiliate AgenTus in addition to early stage and near-commercial antibody programs of Agenus. Prior to that, Dr. Lund was […]

Kanti Thirumoorthy, Ph.D.

Kanti Thirumoorthy

Dr. Thirumoorthy is the Senior Vice President of Technical Operations at Neogene Therapeutics. She has 19 years of experience in the pharmaceutical industry, including in cell therapies, with expertise in technical operations, chemistry, Manufacturing and Control (CMC), quality control and quality assurance/compliance. Before joining Neogene, she spent six years at Kite Pharma, where she most […]

Arianne Perez Garcia, Ph.D.

Arianne Perez

Dr. Perez Garcia is the Vice President of Translational Sciences at Neogene Therapeutics. She has more than 16 years of combined academic and biopharma industry experience in cancer immunology and immunotherapy research supporting preclinical projects for engineered T cell therapies in oncology. Before joining Neogene, she spent nearly seven years at Kite Pharma, where she […]

Mauro P. Avanzi, M.D., Ph.D.

Mauro Avanzi

Dr. Avanzi, an expert in immuno-oncology and adoptive T cell therapy, joined Neogene Therapeutics as Vice President, Clinical Development. Prior to joining Neogene, Dr. Avanzi held a number of positions of increasing responsibility at Kite Pharma, serving most recently as Executive Medical Director, where he supported multiple clinical programs through all stages of development. Dr. […]

Brent Pfeiffenberger, Pharm.D., MBA

Brent Pfeiffenberger

Brent Pfeiffenberger, Pharm.D., MBA, is the Chief Operating Officer at Neogene Therapeutics. At Neogene, Dr. Pfeiffenberger oversees the company’s global business operations. Before joining Neogene, Dr. Pfeiffenberger most recently served as senior vice president, U.S. Oncology, at Bristol Myers Squibb where he oversaw an extensive oncology portfolio. Prior to that, Dr. Pfeiffenberger held several critical […]

Gavin M. Bendle, Ph.D.

Dr. Gavin M. Bendle is the Senior Vice President of Research and Development at Neogene Therapeutics. He has been actively engaged in the field of adoptive T cell therapy of cancer for over 17 years and has co-authored numerous publications on this subject. Before joining Neogene, Dr. Bendle was a Senior Director of Cell Therapy […]

Sean Algeo, CPA

Sean Algeo is the Treasurer and Corporate Controller of Neogene Therapeutics. He also serves as Vice President-Finance at Two River Consulting, LLC, where he is responsible for all financial and accounting activities of Two River and certain of its portfolio companies. Prior to joining Two River in 2018, Mr. Algeo was a Senior Manager at […]

Christopher Wilfong, MBA

Christopher Wilfong is the Chief Business Officer at Neogene Therapeutics. In addition, Mr. Wilfong is an Operating Partner at Two River Consulting, LLC, where he is a co-founder and has held interim management positions in several Two River portfolio companies, including Kite Pharma, Inc., Kronos Bio, Inc., Arno Therapeutics, Inc., and Nile Therapeutics, Inc. Prior […]

David M. Tanen

David Tanen

David M. Tanen is Corporate Secretary of Neogene Therapeutics and a Partner and Co-Founder of Two River Consulting, which specializes in creating, operating and financing development-stage life science companies. Mr. Tanen is also a Co-Founder of Kite Pharma, where he served as an officer and General Counsel from its inception until its acquisition by Gilead […]